Q3 2026 Revenue up 27% year over year to $60.2M · 2¢ of every $1 of revenue kept as net profit · operating margin 9.6%
Geron made $60.2M in Q3 2026 (+27% Y/Y). Operating margin 9.6%, net earnings $1.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Revenue$60.2M
Year over year+27%
Operating margin9.6%
Net earnings$1.4M
Operating cash flow$10.3M
Drawing the Sankey…
Open the interactive Sankey →click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $60.2M in Q3 2026, up 27% year over year and up 5% from the previous quarter.
Operating profit was $5.8M, a 9.6% margin (up 39.0 points year over year). Total costs fell 11% while revenue rose 27%. The fastest-growing cost line was Other operating costs (+473%). Net earnings were $1.4M. The effective tax rate was 0.0%.
Operating cash flow was $10.3M, 761% of net earnings. Non-cash charges added back $137K of depreciation and amortization and $4.8M of share-based compensation. Working capital and other items added $4.0M.
Quarterly history
Quarter
Form
Filed
Revenue
Y/Y
Op. margin
Net earnings
Op. cash flow
Q3 2026
10-Q
Nov 4, 2026
$60.2M
+27%
9.6%
$1.4M
$10.3M
Q2 2026
10-Q
Aug 5, 2026
$57.5M
+17%
-21.7%
−$16.7M
−$15.8M
Q1 2026
10-Q
May 6, 2026
$51.8M
+31%
0.3%
−$3.6M
−$62.9M
Q3 2025
10-Q
Nov 7, 2025
$47.2M
+67%
-29.4%
−$18.4M
−$13.6M
Q2 2025
10-Q
Aug 6, 2025
$49.0M
56×
-25.4%
−$16.4M
−$27.4M
Q1 2025
10-Q
May 7, 2025
$39.6M
130×
-42.2%
−$19.8M
−$48.0M
Charts
Latest (Q3 2026): Y/Y +27%, Q/Q +5%.From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.Latest (Q3 2026): Net income $1.4M, Operating cash flow $10.3M.+145.6% since FY2020: more shares outstanding (issuance, stock pay).Cash $77.6M, short-term investments —, long-term debt — at 2025-12-31.Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
treatment that scientific evidence suggests reduces proliferation of malignant cells, allowing production of new healthy cells, which we believe drives differentiated clinical benefits, potentially altering the underlying course and modifying the
In its own words, from its 10-K, filed Mar 2, 2026.
Geron against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +27% against the peers' median +10%. Operating margin: 9.6% against the peers' median 20.4%.